Vitae Pharmaceuticals Reports Third Quarter 2014 Operating

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Vitae Pharmaceuticals Reports Third Quarter 2014 Operating and Financial Results

FORT WASHINGTON, Pa., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq: VTAE ), a clinical-stage biotechnology company, reported today its operating and financial results for the third quarter ended September 30, 2014.

"The successful completion of our initial public offering in September provides us with additional capital to advance our proprietary pipeline, and, we believe, to achieve a number of key milestones," said Jeffrey Hatfield, President and Chief Executive Officer of Vitae. "In addition, we announced in October positive top-line results from two Phase 1 clinical trials of our BACE inhibitor for Alzheimer's disease that were conducted by our collaboration partner. These positive results are an important first clinical step toward providing to physicians, and ultimately to patients, a novel therapeutic that can potentially prevent or minimize the suffering from this terrible disease."

Quarterly and Recent Highlights

Pipeline Updates:

  • Commenced a Phase 2 clinical trial of VTP-34072 for the treatment of type 2 diabetes as part of Vitae's 11 β HSD1 collaboration with Boehringer Ingelheim (BI). The trial, which commenced in July 2014 and is being conducted by BI, involves 126 type 2 diabetic patients and is expected to have results in the first half of 2015. Vitae received a milestone payment of $6.0 million from BI as a result of the first patient having been dosed in this trial.
  • Announced positive top-line results for the treatment and prevention of Alzheimer's disease as part of the BACE collaboration with BI. Two Phase 1 clinical trials of BI1181181 / VTP-37948 were reported as safe and generally well-tolerated across all dose levels tested. BI1181181 / VTP-37948 demonstrated the ability to lower cerebral spinal fluid (CSF) amyloid beta (A β) levels by more than 80%.The results also indicated a half-life of between 16 and 19 hours, supporting a once-daily dosing profile.
  • Continued to advance VTP-43742, our product candidate to treat autoimmune disorders, toward an anticipated filing of an Investigational New Drug Application (IND), with Phase 1 clinical trials commencing thereafter. Vitae progressed drug manufacturing and other key activities that are expected to enable it to file an IND and initiate Phase 1 clinical trials in the first half of 2015.

Corporate Updates:

  • Successfully completed its initial public offering (IPO) . Vitae issued and sold an aggregate of approximately 7.9 million shares of common stock, including the shares sold upon the exercise of the underwriter's over-allotment option, at a price of $8.00 per share less underwriting discounts, for aggregate proceeds of approximately $56.3 million, net of offering fees and expenses.
  • Appointed Charles Rowland, Jr. and Gino Santini to its Board of Directors. Mr. Rowland was formerly Vice President and Chief Financial Officer of ViroPharma Incorporated and currently serves on the Board of Directors of BIND Therapeutics, Inc. and Aurinia Pharmaceuticals Inc. Mr. Santini was formerly Senior Vice President, Corporate Strategy and Business Development at Eli Lilly and Company and currently serves on the Board of Directors of Horizon Pharma, Inc., AMAG Pharmaceuticals Inc., and Sorin S.p.A., as well as a number of private companies.

Financial Results:

  • Revenue. Collaborative revenues for the third quarter of 2014 were $6.2 million, compared with $5.4 million for the third quarter of 2013. Revenue for the third quarter of 2014 included the $6.0 million milestone payment from BI related to the first patient being dosed in the Phase 2 clinical trial for VTP-34072, while revenue for the third quarter of 2013 included a $4.0 million milestone payment from BI related to the advancement of a back-up compound related to the BACE collaboration.
  • Operating Expense. Total operating expenses for the third quarter of 2014 were $7.9 million, compared with $4.8 million for the third quarter of 2013. This included non-cash stock compensation expense of $2.0 million and $29 thousand in the third quarter of 2014 and 2013, respectively.
    • Research and development expenses were $4.8 million for the third quarter of 2014, compared with $3.5 million for the third quarter of 2013. The increase was largely attributable to expenses related to the RORγt program, including VTP-43742.
    • Selling, general and administrative expenses were $3.1 million for the third quarter of 2014, compared with $1.3 million for the same period in 2013. The increase was largely attributable to expenses related to stock-based compensation of $1.7 million.
  • Net Loss/Income. Vitae reported a net loss of $1.8 million for the third quarter of 2014, compared with net income of $0.2 million for the third quarter of 2013.
  • Cash position. As of September 30, 2014, Vitae had $67.8 million in cash, restricted cash and marketable securities, compared to $32.5 million as of December 31, 2013. The increase was primarily a result of the completion of the company's IPO which raised $48.7 million, net of underwriting discounts and offering expenses, in the third quarter of 2014. Subsequent to the quarter end, the underwriters exercised their over-allotment option for approximately 1 million additional shares, which were purchased at $8.00 per share less underwriting discounts and raised an additional $7.6 million, net of expenses.

Upcoming Milestones:

Vitae reaffirmed the following previously disclosed potential development milestones for its programs in the first half of 2015:

  • VTP-34072 - (11 β HSD1) - Top-line results from the Phase 2 proof of concept trial in type 2 diabetic patients.
  • VTP37948 / BI1181181 - (BACE) - Completion of additional Phase 1 clinical trials, including a multiple rising dose trial.
  • VTP-43742 - (ROR γ t) - Initiation and completion of a single dose Phase 1 safety and PK clinical trial in healthy human volunteers.

Company to Host Conference Call

Vitae will host a conference call today, November 12, 2014, at 4:30 p.m. EST to discuss the company's financial results for the quarter ended September 30, 2014, and recent operational highlights. A question and answer session will follow Vitae's remarks. To participate on the live call, please dial 844-423-9893 (domestic) or +1-716-247-5808 (international), and provide the conference ID 32241442, approximately five to 10 minutes ahead of the start of the call.

A live audio webcast of the call will be available via the "Investor Relations" page of the Vitae website, www.vitaepharma.com . Please log on through Vitae's website approximately 10 minutes prior to the scheduled start time. A replay of the webcast will be archived on Vitae's website for 90 days following the call.

About Vitae Pharmaceuticals

Vitae Pharmaceuticals is a clinical-stage biotechnology company focused on discovering and developing novel, small molecule drugs for diseases in which there are significant unmet medical needs. The company is developing a robust and growing portfolio of novel product candidates generated by Contour®, its proprietary structure-based drug discovery platform.

For additional information, please visit the company's website at www.vitaepharma.com .

Safe Harbor Statement

This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Vitae's and its partner's plans for its product candidates. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "anticipate," "project," "target," "design," "estimate," "predict," "potential," "plan" or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Vitae is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in Vitae's forward-looking statements include, among others, the timing and success of preclinical studies and clinical trials conducted by Vitae and its collaborative partners; the ability to obtain and maintain regulatory approval of Vitae's product candidates, and the labeling for any approved products; the scope, progress, expansion, and costs of developing and commercializing Vitae's product candidates; the size and growth of the potential markets for Vitae's product candidates and the ability to serve those markets; Vitae's expectations regarding Vitae's expenses and revenue, the sufficiency of Vitae's cash resources and needs for additional financing; Vitae's ability to attract or retain key personnel; and other factors that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vitae's final prospectus filed under Rule 424(b)(4) with the Securities and Exchange Commission (SEC) in connection with Vitae's initial public offering. Additional factors may also be set forth in those sections of Vitae's Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 to be filed with the SEC. In addition to the risks described above and in Vitae's other filings with the SEC, other unknown or unpredictable factors also could affect Vitae's results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Vitae undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Vitae Pharmaceuticals, Inc.
Statement of Operations (unaudited)
         
  Three Months Ended
September 30,
Nine Months Ended
September 30,
  2014 2013 2014 2013
Collaborative revenues $ 6,178,166 $ 5,352,230 $ 8,507,113 $ 7,314,528
Operating expenses:        
Research and development  4 ,799,268  3,527,624  14,224,526  11,112,251
General and administrative  3,096,399  1,316,695  5,724,690  3,996,478
Total operating expenses  7,895,667  4,844,319  19,949,216  15,108,729
(Loss) / income from operations  (1,717,501)  507,911  (11,442,103)  (7,794,201)
Other (expenses) income:        
Other income  125,544  —   343,318  303,891
Interest income  7,894  14,335  36,709  57,441
Interest expense  (225,355)  (342,763)  (766,392)  (1,110,978)
Total other (expenses) income  (91,917)  (328,428)  (386,365)  (749,646)
Net (loss) income $ (1,809,418) $ 179,483 $ (11,828,468) $ (8,543,847)
Per share information:        
Net (loss) income per common share:        
Basic $ (1.06) $ 0.00  $ (12.18) $ (15.36)
Diluted $ (1.06) $ 0.00  $ (12.18) $ (15.36)
Weighted‑average number of common shares:        
Basic  1,711,969  564,702  971,439  556,220
Diluted  1,711,969  564,702  971,439  556,220
   
   
Vitae Pharmaceuticals, Inc.  
Selected Balance Sheet Data (unaudited)  
  As of
September 30,
As of
December 31,
  2014 2013
 Cash, Cash Equivalents and Marketable securities   $ 67,806,843  $ 32,454,453
 Working Capital   58,362,135  23,905,376
 Current Liabilities   10,898,413  9,517,419
 Convertible Preferred Stock  0  125,869,931
 Common Stock and APIC   180,864,663  3,983,281
 Total Stockholder's equity / (deficit)   58,154,269  (106,894,151)

INVESTORS: Vitae Pharmaceuticals, Inc. Richard S. Morris, CPA Chief Financial Officer (215) 461-2000 Westwicke Partners John Woolford (443) 213-0506 MEDIA: 6 Degrees PR Tony Plohoros (908) 940-0135

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Rokt's 164% Growth Shows Checkout Ads Have Real Muscle

Updated Category News Views 116

Checkout screens have become valuable real estate, and Rokt is planting a flag right in the middle of them. The New York ecommerce technology company landed on Deloitte's 2026 Technology Fast 500 after posting 164% revenue growth from 2022 through 2025. That is a meaningful number, not decorative corporate confetti, especially in a digital-ad market where plenty of...

Continue Reading
Trucking Hub Bets on Faster MVR Checks Nationwide Today

Updated Category News Views 98

Driver paperwork is where plenty of supposedly modern fleet systems still go to die. Trucking Hub’s Nov. 18 launch of GetMVR.com takes a clean swing at that mess: an online platform for ordering Motor Vehicle Records in all 50 states, with instant reports available in 48. It is not glamorous software, and frankly that is why it may matter. Fleets do not lose sleep over...

Continue Reading
Marina del Rey's Travel Award Brings Fresh Attention

Updated Category News Views 56

A harbor town just got handed a useful little megaphone. On November 18, 2026, the Marina del Rey Tourism Board said Marina del Rey had been selected as a winner in Good Housekeeping's 2027 Travel Awards. That is not a quarterly earnings event, and nobody ought to dress it up as one. Still, in the visitor economy, recognition from a broad consumer publication can matter...

Continue Reading
WYBOT's New Robots Push Hands-Free Pool Care in Lyon

Updated Category News Views 64

A pool robot climbing out of the water to dock itself is the sort of demo that makes people stop mid-aisle at a trade show. WYBOT brought precisely that kind of attention-grabber to Piscine Global Lyon 2026, running November 17–20 at Eurexpo Lyon. The company is showing a broader lineup, but the M3 Pro is plainly the headline act: WYBOT calls it the world's first...

Continue Reading
Whole-House Remodels Need a Plan Before Any Finishes

Updated Category News Views 14

A remodel gets expensive the minute somebody falls in love with tile before checking what sits behind the wall. Adam Sherman’s central point in the HelloNation article is refreshingly unglamorous: treat the house as one working system before treating it as a collection of rooms crying out for cosmetic rescue. That sounds obvious until you see how often a kitchen...

Continue Reading
Somerville’s New Immersive Bet Has Room to Grow Locally

Updated Category News Views 74

A passcard, a hidden door, and 12,000 square feet of mischief have landed at Somernova. Edge of Elsewhere, the new flagship attraction from Boston-area creative studio Midnight Mansion, is open in Somerville’s Union Square as of November 18, 2026. It is part interactive art installation, part puzzle game, part physical story world. That sounds delightfully odd, which is...

Continue Reading
Linkind's Best Buy Push Tests Smart Outdoor Demand

Updated Category News Views 160

Holiday lights have quietly become a year-round hardware category, and Linkind wants a louder seat at the table. The smart-lighting brand says three outdoor products have been in Best Buy stores across the United States since October 17, 2026: permanent exterior lights, decorative string lights, and solar pathway lights. That is a real distribution step, not some grand...

Continue Reading
Kids First Data Sharing Raises Pediatric Research Bar

Updated Category News Views 98

Thirty-eight thousand children’s records are not a headline gimmick; they are a serious argument for treating research data as an asset that must keep working after the first study ends. The Gabriella Miller Kids First Data Resource Center’s ten-year review, published in the September 2026 issue of The American Journal of Human Genetics, makes that argument with...

Continue Reading
illumine Targets Childcare Chain Control and Risk Gaps

Updated Category News Views 62

Expansion Gets Messy Before It Gets Impressive Childcare operators do not usually stumble because they forgot how to care for children; they stumble because the back office fractures as the network grows. One center handles fees one way, another lets enrollment leads work a different funnel, and headquarters discovers too late that its reports are arguing with each other....

Continue Reading
Specialty Chemicals Need Demand Before Capacity Bets

Updated Category News Views 83

Empty reactor space does not get filled because everybody suddenly loves reshoring. SOCMA's 2027 Contract Manufacturing Outlook makes that stubborn fact hard to dodge: nearly 70% of surveyed respondents expect North American manufacturing activity to rise over the next three years, yet 79.5% say stronger, more predictable customer demand is critical before future...

Continue Reading

Top 5 Most Recently Viewed Articles

CREFC's 1Q Sentiment Index Reflects Industry Concerns

Updated Category News Views 225

Understanding the Decline in CREFC's Sentiment Index The CRE Finance Council (CREFC), representing the vast $6.2 trillion commercial and multifamily real estate finance sector, recently unveiled its latest survey results. The 1Q 2025 Sentiment Index, which is an essential barometer for industry sentiment, has experienced a steep dive, marking a significant shift in...

Continue Reading
Rubicon Organics Inc. Posts Impressive Growth in 2024 Results

Updated Category News Views 26025

Financial Highlights of 2024 Rubicon Organics Inc. has announced outstanding financial results for the year ended December 31, 2024. The Company, a prominent player in the organic cannabis sector, reported a record high net revenue of $48.7 million, which is a prestigious 21% increase from the previous year. In the fourth quarter alone, Rubicon Organics realized a net...

Continue Reading
Amazon Web Services Boosts Cloud Capacity with $5 Billion Venture

Updated Category News Views 134

Amazon Web Services Expands Reach in Asia Pacific Amazon.com, Inc. (NASDAQ: AMZN), through its cloud computing branch, Amazon Web Services (AWS), has recently announced the establishment of the AWS Asia Pacific (Thailand) Region. This expansion comes with an impressive planned investment exceeding $5 billion. Investment Insights and Customer Benefits This significant...

Continue Reading
Cellectar Biosciences Secures $5.8 Million Through Warrant Exercise

Updated Category News Views 200

Significant Fundraising by Cellectar Biosciences In an exciting development for the biotechnology sector, Cellectar Biosciences, Inc. (NASDAQ: CLRB), a leading company focused on advancing cancer treatments, has successfully raised approximately $5.8 million through a strategic agreement with multiple institutional investors. This figure represents the gross proceeds from...

Continue Reading
Waldorf Astoria Hosts Dazzling Tennis Event in Ballroom

Updated Category News Views 43

Tennis in the Heart of Luxury Well, here’s a twist that even Arthur Ashe couldn’t have envisioned—the famed Waldorf Astoria in New York is rolling out the green carpet right there in their iconic ballroom. On August 27, they're busting out the tennis rackets where chandeliers usually watch ballroom dancing. You know, once in a while, even us grizzled investors have...

Continue Reading